[go: up one dir, main page]

Burgos Espadinha, 2016 - Google Patents

Exploring combined treatment strategies to target quiescent chronic myeloid leukemia (CML) stem cells

Burgos Espadinha, 2016

View PDF
Document ID
4156330267937898706
Author
Burgos Espadinha D
Publication year

External Links

Snippet

Chronic myeloid leukemia (CML) was one of the first malignancies suggested to be driven by leukemic stem cells (LSCs) and currently serves as a disease model for stem cell based malignancies. The constitutively active BCR-ABL tyrosine kinase, created by a reciprocal …
Continue reading at archiv.ub.uni-heidelberg.de (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Similar Documents

Publication Publication Date Title
Liu et al. Sinomenine inhibits the progression of rheumatoid arthritis by regulating the secretion of inflammatory cytokines and monocyte/macrophage subsets
Juntilla et al. AKT1 and AKT2 maintain hematopoietic stem cell function by regulating reactive oxygen species
Kobayashi et al. Macrophage-T cell interactions mediate neuropathic pain through the glucocorticoid-induced tumor necrosis factor ligand system
Burberry et al. Infection mobilizes hematopoietic stem cells through cooperative NOD-like receptor and Toll-like receptor signaling
Kim et al. NRF2-mediated Notch pathway activation enhances hematopoietic reconstitution following myelosuppressive radiation
US11116819B2 (en) Methods and compositions for mobilizing stem cells
Zhang et al. Matrix metalloproteinase-9 and stromal cell-derived factor-1 act synergistically to support migration of blood-borne monocytes into the injured spinal cord
Costello et al. MRTF-SRF signaling is required for seeding of HSC/Ps in bone marrow during development
Collins et al. Maternal inflammation regulates fetal emergency myelopoiesis
Chao et al. Downregulated CXCL12 expression in mesenchymal stem cells associated with severe aplastic anemia in children
Yin et al. Protective effects of CXCR3/HO-1 gene-modified BMMSCs on damaged intestinal epithelial cells: Role of the p38-MAPK signaling pathway
Gogoleva et al. Current perspectives on the role of TNF in hematopoiesis using mice with humanization of TNF/LT system
Frelin et al. Grb2 regulates the proliferation of hematopoietic stem and progenitors cells
Fleenor et al. Contrasting roles for C/EBPα and Notch in irradiation-induced multipotent hematopoietic progenitor cell defects
Suzuki et al. Impairment of fetal hematopoietic stem cell function in the absence of Fancd2
US20110135651A1 (en) Method and composition for enhancing hematopoietic stem cell mobilization
CA3051590A1 (en) Prophylaxis and treatment of acute myeloid leukemia
Hostler et al. Endothelial‐specific CXCL12 regulates neovascularization during tissue repair and tumor progression
Lettera et al. Molecular and phenotypic blueprint of the hematopoietic compartment reveals proliferation stress as a driver of age-associated human stem cell dysfunctions
Burgos Espadinha Exploring combined treatment strategies to target quiescent chronic myeloid leukemia (CML) stem cells
De Vita et al. The gp130 cytokine interleukin-11 regulates engraftment of Vav1–/–hematopoietic stem and progenitor cells in lethally irradiated recipients
US20090035318A1 (en) Method and composition for increasing the engraftment efficiency of stem cells
Li et al. Interleukin 8/KC enhances G-CSF induced hematopoietic stem/progenitor cell mobilization in Fancg deficient mice
Bohrer et al. Eosinophils are an integral component of the pulmonary granulocyte response in Tuberculosis and promote host resistance in mice
Williams et al. Maintenance of haematopoietic stem cells by JAK inhibition and increased tyrosine-unphosphorylated STAT5